Jump to main content
Topic: Policy
-
Dissecting PhRMA’s Opposition to H.R. 3 Lower Drug Costs Now Act of 2019
Read More
-
Fact Checking the NYT Fact Check on the Trump Proposal
Read More
-
Understanding the Rewards of Successful Drug Development: Thinking Inside the Box
Read More
-
Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection
Read More
-
Fact Check: Time to Market for New Drugs in U.S. Versus Other Countries
Read More
-
List Price, Net Price, and the Rebate Caught in the Middle
Read More
-
Perspective on National Coverage Analysis of CAR-T Therapies
Read More
-
DPL responds to HHS Blueprint (May 16, 2018)
Read More
-
Impact of President Trump’s Proposed 340B Hospital Eligibility Threshold
Read More
-
Does the 6% in Medicare Part B Drug Reimbursement Affect Prescribing?
Read More